ArticleGenes and immunity2010
B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele.
Article in Genes and immunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- CD19 Deficiency Leads to Dysregulation of Phosphoinositide 3-Kinase-Protein Kinase B (Journal of clinical practice and research · 2025Article
- A novel homozygous frameshift mutation likely causing nonsense-mediated mRNA decay in an Algerian kindred with CD19 complex deficiency.Frontiers in immunology · 2025Article
- Inherited CD19 Deficiency Does Not Impair Plasma Cell Formation or Response to CXCL12.Journal of clinical immunology · 2023Article
- Cryo-EM structure of the B cell co-receptor CD19 bound to the tetraspanin CD81.Science (New York, N.Y.) · 2021Article
- B Cell Disorders in Children-Part I.Current allergy and asthma reports · 2020Review
- Dissection of the Pre-Germinal Center B-Cell Maturation Pathway in Common Variable Immunodeficiency Based on Standardized Flow Cytometric EuroFlow Tools.Frontiers in immunology · 2020Article
- Age-related alterations of the CD19 complex and memory B cells in children with Down syndrome.Clinical and experimental medicine · 2018Article
- Fcµ Receptor Promotes the Survival and Activation of Marginal Zone B Cells and Protects Mice against Bacterial Sepsis.Frontiers in immunology · 2018Article
- "Immune TOR-opathies," a Novel Disease Entity in Clinical Immunology.Frontiers in immunology · 2018Review
- Reference values for B-cell surface markers and co-receptors associated with primary immune deficiencies in healthy Turkish children.International journal of immunopathology and pharmacology · 2017Article
- CD19 controls Toll-like receptor 9 responses in human B cells.The Journal of allergy and clinical immunology · 2016Article
- Reduced CD19 expression and decreased memory B cell numbers in transient hypogammaglobulinemia of infancy.Clinical and experimental medicine · 2013Article
- Common variable immune deficiency in children--clinical characteristics varies depending on defect in peripheral B cell maturation.Journal of clinical immunology · 2013Article
- Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.Arthritis research & therapy · 2012Review
- New frontiers of primary antibody deficiencies.Cellular and molecular life sciences : CMLS · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Homozygous CD19 mutations lead to an antibody deficiency due to disruption of the CD19 complex and consequent impaired signaling by the B-cell antigen receptor. We studied the effects of heterozygous CD19 mutations on peripheral B-cell development and antibody responses in a large family with multiple consanguineous marriages. Sequence analysis of 96 family members revealed 30 carriers of the CD19 mutation. Lymphocyte subset counts were not significantly different between carriers and noncarriers in three different age groups (0-10 years; 11-18 years; adults). B cells of carriers had reduced CD19 and CD21 median expression levels, and had reduced proportions of transitional (0-10 years) and CD5(+) B cells (adults). CD19 carriers did not show clinical signs of immunodeficiency; they were well capable to produce normal serum Ig levels and had normal responses to primary and booster vaccinations. The frequency of mutated Vκ alleles was not affected. Heterozygous loss of CD19 causes some changes in the naive B-cell compartment, but overall in vivo B-cell maturation or humoral immunity is not affected. Many antibody deficiencies are not monogenetic, but likely caused by a combination of multiple genetic variations. Therefore, functional analyses of immune cell function should be carried out to show whether heterozygous mutations contribute to disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.